Oric Pharmaceuticals Inc
ORIC10.780USD
-0.080-0.74%
Cierre 09/12, 16:00（ET）Cotizaciones retrasadas 15 min
929.10MCap. mercado
PérdidaP/E TTM
Más Datos de Oric Pharmaceuticals Inc Compañía
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Información de la empresa
Símbolo de cotizaciónORIC
Nombre de la empresaOric Pharmaceuticals Inc
Fecha de salida a bolsaApr 24, 2020
Director ejecutivoDr. Jacob M. Chacko, M.D.
Número de empleados115
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 24
Dirección240 E. Grand Ave
CiudadSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Teléfono16503885600
Sitio Webhttps://oricpharma.com/
Símbolo de cotizaciónORIC
Fecha de salida a bolsaApr 24, 2020
Director ejecutivoDr. Jacob M. Chacko, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
778.65K
+1.01%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
228.77K
--
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Independent Director
Independent Director
--
--
Dr. Lori A. Kunkel, M.D.
Dr. Lori A. Kunkel, M.D.
Independent Director
Independent Director
--
--
Dr. Angie J. You, Ph.D.
Dr. Angie J. You, Ph.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jacob M. Chacko, M.D.
Dr. Jacob M. Chacko, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
778.65K
+1.01%
Dr. Richard A. (Rich) Heyman, Ph.D.
Dr. Richard A. (Rich) Heyman, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
228.77K
--
Dr. Kevin Brodbeck, Ph.D.
Dr. Kevin Brodbeck, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Mr. Dominic G. Piscitelli, CPA
Mr. Dominic G. Piscitelli, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik S. Multani, M.D.
Dr. Pratik S. Multani, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Mardi C. Dier
Ms. Mardi C. Dier
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: dom., 31 de ago
Actualizado: dom., 31 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
Otro
66.60%
Accionistas
Accionistas
Proporción
Nextech Invest, Ltd.
7.37%
EcoR1 Capital, LLC
6.93%
VR Adviser, LLC
6.79%
Viking Global Investors LP
6.77%
Pfizer Inc
5.54%
Otro
66.60%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
28.79%
Investment Advisor
26.57%
Venture Capital
22.65%
Hedge Fund
14.71%
Corporation
5.54%
Private Equity
2.02%
Sovereign Wealth Fund
1.98%
Individual Investor
1.43%
Research Firm
1.21%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
288
93.19M
110.15%
+12.20M
2025Q1
294
83.96M
99.59%
+456.78K
2024Q4
284
80.39M
113.18%
-3.73M
2024Q3
272
78.70M
112.04%
-2.29M
2024Q2
265
76.25M
113.03%
-1.57M
2024Q1
276
71.21M
105.62%
-1.02M
2023Q4
259
57.91M
108.09%
+1.21M
2023Q3
260
55.20M
103.62%
-1.09M
2023Q2
255
52.76M
117.11%
+8.95M
2023Q1
257
40.28M
89.44%
-3.51M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Nextech Invest, Ltd.
5.29M
6.2%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
3.42M
4.01%
--
--
Mar 31, 2025
VR Adviser, LLC
6.60M
7.74%
+3.41M
+107.28%
Apr 08, 2025
Viking Global Investors LP
6.57M
7.71%
+2.14M
+48.33%
Mar 31, 2025
Pfizer Inc
5.38M
6.31%
--
--
Mar 31, 2025
SR One Capital Management, LP
4.62M
5.42%
+4.62M
--
May 29, 2025
New Enterprise Associates (NEA)
2.20M
2.58%
+629.46K
+40.19%
Mar 31, 2025
Alkeon Capital Management LLC
3.34M
3.92%
+86.63K
+2.66%
Mar 31, 2025
The Column Group LP
3.54M
4.15%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.40M
5.16%
+59.93K
+1.38%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
iShares Genomics Immunology and Healthcare ETF
0.93%
SPDR S&P Biotech ETF
0.11%
iShares Micro-Cap ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.05%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Ver más
iShares Genomics Immunology and Healthcare ETF
Proporción0.93%
SPDR S&P Biotech ETF
Proporción0.11%
iShares Micro-Cap ETF
Proporción0.1%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.06%
iShares Biotechnology ETF
Proporción0.05%
Fidelity Enhanced Small Cap ETF
Proporción0.05%
Avantis US Small Cap Equity ETF
Proporción0.05%
Vanguard US Momentum Factor ETF
Proporción0.03%
ProShares Hedge Replication ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
